So-Young International Inc.
HealthcareNASDAQ:SY · NASDAQ Global Market
-$0.11 today
Vol 0.74M · Avg 0.62M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$1.6B of revenue converted into -$256.5M of net income for the selected period. Gross margin is 46.3% and net margin is -15.3%, showing how much revenue survives after costs and taxes. EPS is $-1.95, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5B +1.0% | $1.5B -2.1% | $1.5B +19.1% | $1.3B -25.7% | $1.7B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $774.0M +36.4% | $567.6M +4.3% | $544.3M +38.4% | $393.3M +19.9% | $327.9M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $707.9M -21.3% | $899.1M -5.7% | $953.7M +10.3% | $864.6M -36.6% | $1.4B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 47.8% -13.5pp | 61.3% -2.4pp | 63.7% -5.1pp | 68.7% -11.9pp | 80.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $133.3M -19.2% | $165.0M -18.9% | $203.5M -13.4% | $235.1M -18.0% | $286.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $833.8M +1.9% | $818.6M +0.9% | $811.2M +10.8% | $732.3M -29.9% | $1.0B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $967.1M -36.5% | $1.5B +50.1% | $1.0B +4.9% | $967.4M -30.8% | $1.4B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $0 -100.0% | $46.1M +0.0% | $46.1M -2.1% | $47.1M +56.5% | $30.1M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$239.4M -523.6% | -$38.4M -171.2% | $54.0M +234.9% | -$40.0M -163.1% | $63.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -16.2% -13.5pp | -2.6% -6.2pp | 3.6% +6.8pp | -3.2% -6.9pp | 3.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$259.2M +58.5% | -$624.5M -923.0% | -$61.0M +40.6% | -$102.8M -215.6% | -$32.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -17.5% +25.1pp | -42.6% -38.5pp | -4.1% +4.1pp | -8.2% -6.2pp | -1.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $24.6M -47.1% | $46.5M -4.8% | $48.8M +69.1% | $28.9M +49.4% | $19.3M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $19.8M -45.6% | $36.4M -47.2% | $68.9M +338.0% | $15.7M -2.7% | $16.2M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$239.4M +59.3% | -$588.1M -7573.5% | $7.9M +109.0% | -$87.1M -430.8% | -$16.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -16.2% +23.9pp | -40.1% -40.6pp | 0.5% +7.4pp | -6.9% -6.0pp | -1.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$774.3K +14.4% | -$905.0K +95.0% | -$18.1M +13.8% | -$21.0M -198.7% | $21.2M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$235.7M +60.0% | -$589.5M -2870.3% | $21.3M +132.5% | -$65.6M -683.1% | -$8.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | -15.9% +24.3pp | -40.2% -41.6pp | 1.4% +6.6pp | -5.2% -4.7pp | -0.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +59.5% | -$4 -2850.0% | $0 +133.3% | -$0 -692.1% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +59.5% | -$4 -2843.8% | $0 +133.3% | -$0 -692.1% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $131.6M -1.9% | $134.1M +0.7% | $133.2M -3.5% | $138.0M +0.0% | $138.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $131.6M -1.9% | $134.2M +1.7% | $131.9M -4.4% | $138.0M +0.0% | $138.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$852.86M
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
$841.97M
Sonida Senior Living, Inc.
NYSE:SNDA
$700.96M
Omeros Corporation
NASDAQ:OMER
$632.20M
Varex Imaging Corporation
NASDAQ:VREX
$464.78M
SOPHiA GENETICS S.A.
NASDAQ:SOPH
$349.74M
Standard BioTools Inc.
NASDAQ:LAB
$346.53M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$329.81M
Simulations Plus, Inc.
NASDAQ:SLP
$329.75M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SY generate?
So-Young International Inc. (SY) reported $1.48B of revenue in fiscal 2025.
Is SY profitable?
So-Young International Inc. (SY) reported -$235,699,547.00 of net income, with a net margin of -15.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.